Alpha Tau Medical

⭐ Median overall survival (OS) of 18.2 months ⭐ Median progression-free survival (PFS) of 5.4 months ⭐ No Alpha DaRT-associated serious adverse events were observed ⭐ Trial recruitment is now complete, having met the pre-specified success criterion "Combination trials like this one are central to how we intend to grow the platform. Showing that #AlphaDaRT can be added to a systemic backbone safely, and with results like these, is exactly the kind of evidence we hope will define its role across our pipeline. And we won’t stop here" Uzi Sofer, CEO For full PR - Check the first comment

Alpha Tau Medical Successfully Treats First #Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma (#cSCC) in its #ADMIRE Study at Banner MD Anderson Cancer Center ❇️ The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Samuels, has also treated multiple patients ❇️ Immunocompromised patients face dramatically higher rates of cSCC, the second most common type of skin cancer in the U.S., than the general population - as much as 65- to 100-fold among organ transplant recipients specifically ❇️ For many patients in this population, the general treatment options for recurrent cSCC can actually cause real harm: checkpoint inhibitor immunotherapy, the standard option for the general population, carries a documented risk of triggering rejection of a transplanted organ - For full PR - check the first comment

At #AHNS2026 in Boston, Alpha Tau Medical will share new results evaluating #AlphaDaRT® in combination with #pembrolizumab in patients with locally advanced or metastatic head and neck squamous cell carcinoma (#HNSCC). The abstract has been selected for presentation during the Proffered Papers session on Radiation and Adjuvant Therapies, where Prof. Aron Popovtzer, MD, will present the findings on Tuesday, July 21, between 10:30 AM-12:00 PM. We will also be hosting a dedicated event for leading head and neck surgeons on Monday, July 20, and our team will be on-site with a booth and head and neck procedure demo throughout the conference. We look forward to meaningful conversations in Boston and to sharing what we believe is an important step forward for Alpha DaRT in head and neck cancer. More to come.

Can #AlphaDaRT outsmart the liver's tolerance for tumors? Nature’s Scientific Reports journal recently published a preclinical study of the immune-activating effects of Alpha DaRT®, using a unique model designed to capture what actually happens when a colorectal tumor sits inside the liver. We sat down with Dr. Oran Zlotnik, Dr. Vered D. , and Ronen Segal to talk through what they discovered, and why it matters. The liver is a rare organ in the body whose function is to clear the body from toxins, so naturally it lowers its radar against foreign invaders, making it easier for them to hide and grow. So when a tumor forms in the liver, the body’s natural immune response to fight the tumor is relatively weak. Colorectal cancer exploits exactly this weakness when it spreads to the liver, which is a major reason immunotherapy so often fails there. What the recent study shows is that even inside this immune-suppressed environment, a single intratumoral Alpha DaRT source still activated the immune system. Tumors shrank threefold in just 7 days, the surrounding healthy liver tissue stayed intact, and at the tumor's border, the immunosuppressive macrophages that normally block immune access were significantly reduced, while cancer-killing T cells moved in. Just as important: this is the first time the Alpha DaRT has been shown in an orthotopic model that actually replicates the disease. Most colorectal liver metastasis research, even when it's technically "colorectal," is actually done using tumors grown under the skin. This study used a tumor growing inside the liver itself, in its real immune environment, because there’s no better way to know if this actually works where it matters. This research could potentially unlock a new way of treating the particularly challenging case of colorectal metastases in the liver. For the full interview - check the first comment

“𝑴𝒚 𝒖𝒏𝒆𝒙𝒑𝒆𝒄𝒕𝒆𝒅 𝒋𝒐𝒖𝒓𝒏𝒆𝒚 𝒐𝒏 𝒕𝒉𝒆 𝒘𝒂𝒚 𝒕𝒐 𝒄𝒉𝒂𝒏𝒈𝒊𝒏𝒈 𝒄𝒂𝒏𝒄𝒆𝒓 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔’ 𝒍𝒊𝒗𝒆𝒔.”  𝘈𝘭𝘦𝘹𝘢𝘯𝘥𝘳𝘦 "𝘚𝘩𝘢𝘪𝘬𝘦" 𝘚𝘵𝘢𝘶𝘣𝘦𝘳 The most unexpected journeys often lead to the most important work happen when a physicist sits next to a clinician, when an engineer challenges a researcher, when a marketing mind asks the question a scientist forgot to ask. At Alpha Tau Medical, this is exactly how we work - physicists, R&D teams, engineers, clinical experts, and business minds, all advancing #AlphaDaRT® from a single shared belief: that the hardest problems in cancer treatment demand every perspective at the table. But diversity of discipline is only part of the story. What truly sets a team apart is diversity of background, not just what people know, but who they are and where they came from. Life experience shapes intuition. Uncommon paths produce uncommon thinking. And it is that combination, of expertise and lived experience, that we believe makes Alpha Tau one of the most exciting clinical-stage oncology companies today. This week, a major Israeli news outlet featured the story of our own, Alexandre "Shaike" Stauber, and it is a story that captures this spirit perfectly. Educated in a strict system without any formal scientific curriculum, Shaike encountered elementary mathematics for the first time at the age of 29. He went on to study physics at Hebrew University, and today is an integral part of the team bringing Alpha DaRT® into oncology wards around the world. Shaike's journey is extraordinary by any measure. But at Alpha Tau, it is also deeply familiar, because this is the kind of person, and the kind of story, we are proud to be built from. Shaike, we are proud to have you with us. 🩵 💙 🩵 For the full article - check the first comment

Alpha Tau Medical Successfully Treats First Recurrent #Glioblastoma Patient Outside of the United States with #AlphaDaRT® at #Hadassah University Medical Center in Israel "𝘛𝘩𝘦 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦 𝘸𝘢𝘴 𝘤𝘰𝘮𝘱𝘭𝘦𝘵𝘦𝘥 𝘴𝘶𝘤𝘤𝘦𝘴𝘴𝘧𝘶𝘭𝘭𝘺, 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘶𝘯𝘦𝘹𝘱𝘦𝘤𝘵𝘦𝘥 𝘤𝘰𝘮𝘱𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴, 𝘢𝘯𝘥 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘢𝘯 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘱𝘳𝘰𝘰𝘧 𝘰𝘧 𝘤𝘰𝘯𝘤𝘦𝘱𝘵 𝘧𝘰𝘳 𝘩𝘰𝘸 𝘵𝘩𝘦 𝘧𝘭𝘦𝘹𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘈𝘭𝘱𝘩𝘢 𝘋𝘢𝘙𝘛'𝘴 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘺 𝘴𝘺𝘴𝘵𝘦𝘮 𝘤𝘢𝘯 𝘣𝘦 𝘢𝘥𝘢𝘱𝘵𝘦𝘥 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹𝘪𝘵𝘺 𝘰𝘧 𝘪𝘯𝘥𝘪𝘷𝘪𝘥𝘶𝘢𝘭 𝘣𝘳𝘢𝘪𝘯 𝘵𝘶𝘮𝘰𝘳 𝘢𝘯𝘢𝘵𝘰𝘮𝘺" 𝐏𝐫𝐨𝐟. 𝐘𝐢𝐠𝐚𝐥 𝐒𝐡𝐨𝐬𝐡𝐚𝐧, Professor of Neurosurgery at Hadassah University Medical Center For full PR - Check the first comment

Alpha Tau Medical Receives FDA Clearance to Complete Enrollment in #REGAIN Recurrent #Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control "Glioblastoma is one of the most devastating diagnoses in oncology and is a core strategic indication for the Company. Since the fantastic interim results we released last month from our first three recurrent GBM treatments, clinicians have been overwhelmingly demanding that we keep treating patients as quickly as possible. This clearance, combined with the expansion to additional leading U.S. centers, hopefully brings us meaningfully closer to making Alpha DaRT a real option for these patients."  𝑼𝒛𝒊 𝑺𝒐𝒇𝒆𝒓, 𝑪𝑬𝑶 For full PR - Check the first comment

Alpha Tau Medical and Tolmar Announce Strategic Collaboration to Bring #AlphaDaRT® Therapy to U.S. #Urological Cancer Patients 🔵 Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape 🔵 Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar’s initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication 🔵 Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments 🔵 Alpha Tau to manufacture Alpha DaRT for Tolmar’s commercialization, to be sold to Tolmar at 60% of the onward net sales price, subject to certain adjustments For full PR - Check the first comment 

#AlphaTau Announces Strong Overall Survival Results from #AlphaDaRT #PancreaticCancer Studies Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting ✅ Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey ✅ Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations ✅ Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for metastatic patients and ~ 9 months for locally advanced patients with second-line chemotherapy, based on published historical data ✅ Favorable safety profile observed across the Alpha DaRT trials, with treatment-associated adverse events reported in 36% of subjects and Grade ≥3 events in 9%, with no treatment-related deaths and no chronic toxicity; all Grade ≥3 events resolved ✅ Following these strong survival data, Company next turns to anticipated completion of recruitment in the multicenter U.S. IMPACT pancreatic cancer trial, which is exploring the ability of Alpha DaRT, in combination with initiation of front-line chemotherapy, to deliver a potent and focused local dose without exacerbating the harsh systemic side effects of standard chemotherapy For full PR - check the first comment

Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.